Caris Life Sciences (CAI) Q2 FY26 earnings call: guidance and Q&A

What drove the reacceleration of total clinical volume from Q1 to Q2, and was any Q1 disruption recaptured?

Management attributed the reacceleration to the sales team's effective work post-realignment, leading to record sequential case additions. Even excluding Q1 rollover cases, Q2 was a record for sequential growth, particularly in tissue volume, while blood volume continued strong growth.

“But seeing those KPIs play out in Q2 and the great work done by the sales team once they're starting to mature, that's what's given us confidence as we go in.”

asked by Michael Ryskin · answered by Luke Power

Where will the company reinvest its positive EBITDA and cash flow in H2, and what is the status of lab build-out CapEx?

Reinvestment is focused on a $47 million inventory ramp-up for Caris Detect, additional sequencing capabilities, and continued CapEx for lab build-out, with $15 million to $20 million expected in Q3. The goal is to get ahead of anticipated Detect volume.

“So that's what the bulk of the cash is going to be utilized for in Q3. And then from a CapEx standpoint, yes, we spent $22 million. We're going to continue to build out.”

asked by Michael Ryskin · answered by Luke Power

Does the updated guidance include any contribution from new product launches like Caris Detect or MRD, or is it solely from existing business strength?

The raised guidance is purely based on the existing molecular profiling business. No contribution from Caris Detect or other new launches is assumed in the current guidance, as the company prefers to establish a history of performance before including them.

“It's -- yes, it's basically -- it's our existing business. We're not assuming anything for Detect. We've been quite clear like when we launch new products, we're going to give it a quarter or 2.”

asked by Vijay Kumar · answered by Luke Power

When will Caris Detect move beyond being capacity constrained, and how is the company balancing the Everlywell partnership with its own sales force for MCED?

Current Detect capacity is $1 billion/year, tripling to $3 billion/year, but back orders are still anticipated. The company is launching an aggressive direct-to-consumer ad campaign soon and primarily using channel partners like Everlywell, rather than dedicating its own sales team directly to Detect.

“Our current capacity is about $1 billion a year of revenue, and we're just about to triple that. So that will be about $3 billion a year in revenue, and we're still worried about back orders.”

asked by Tycho Peterson · answered by David Halbert

How might looking at additional sequencing suppliers change the economics of each test in the long term?

New sequencing suppliers offer significantly higher throughput and lower costs compared to existing options. This creates an opportunity to simultaneously increase capacity and decrease the cost of goods.

“So there are 2 competitors out there now against the long-standing sequencing supplier, and they're their throughput and their cost is significantly higher and lower, respectively, than what's available. So they create the opportunity to increase our capacity and decrease our cost of goods simultaneously.”

asked by Elizabeth Koslosky · answered by David Spetzler

What is the competitive landscape like, especially with accelerating growth from blood leaders, and how is Caris stacking up in terms of blood and tissue usage and gaining market share?

Management sees significant opportunity in the early innings of precision oncology, emphasizing the large and growing TAM. They believe their comprehensive Whole Exome/Whole Transcriptome technology is superior and that execution, including sales force investment and programmatic approach with the Precision Oncology Alliance, is key to capturing market share against both narrow panels and competitors.

“So for us, it's really all about execution and delivering that technology and those services as broadly as possible. So the things that Luke was talking about in terms of what we're doing in the commercial investment is very important.”

asked by Daniel Brennan · answered by Brian Brille